Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. [electronic resource]
Producer: 20021122Description: 1917-24 p. digitalISSN:- 0002-9440
- Animals
- Antibodies, Monoclonal -- therapeutic use
- Antineoplastic Agents, Phytogenic -- therapeutic use
- Apoptosis
- Ascites -- prevention & control
- Carcinoma -- drug therapy
- Cell Division
- Combined Modality Therapy
- Endothelial Growth Factors -- antagonists & inhibitors
- Female
- Intercellular Signaling Peptides and Proteins -- immunology
- Lymphokines -- antagonists & inhibitors
- Mice
- Mice, Nude
- Neutralization Tests
- Ovarian Neoplasms -- drug therapy
- Paclitaxel -- therapeutic use
- Tumor Cells, Cultured
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factors
No physical items for this record
Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.